FMP

FMP

Enter

VYGR - Voyager Therapeutics...

Financial Summary of Voyager Therapeutics, Inc.(VYGR), Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and nex

photo-url-https://financialmodelingprep.com/image-stock/VYGR.png

Voyager Therapeutics, Inc.

VYGR

NASDAQ

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

8.67 USD

-0.01 (-0.115%)

About

ceo

Dr. Alfred W. Sandrock Jr., M.D., Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.voyagertherapeutics.com

exchange

NASDAQ

Description

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosci...

CIK

0001640266

ISIN

US92915B1061

CUSIP

92915B106

Address

75 Sidney Street

Phone

857 259 5340

Country

US

Employee

162

IPO Date

Nov 11, 2015

Summary

CIK

0001640266

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

92915B106

ISIN

US92915B1061

Country

US

Price

8.67

Beta

1.04

Volume Avg.

585.9k

Market Cap

471.59M

Shares

-

52-Week

6.06-14.07

DCF

8.48

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-51

P/B

-

Website

https://www.voyagertherapeutics.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest VYGR News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep